<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Mortality in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) patients with <z:hpo ids='HP_0011713'>left bundle branch block</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e>) is high </plain></SENT>
<SENT sid="1" pm="."><plain>Cardiac resynchronization therapy (CRT) reduces symptoms and mortality in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Whether CRT promotes or prevents <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT)/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) remains controversial, however </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we aimed to analyse <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>-related CRT effects and characterized the VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> incidence in CRT-defibrillator patients and matched controls with conventional implantable cardioverter-defibrillators (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>) for primary prevention of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS AND RESULTS: We enrolled 134 patients [110 men, left ventricular ejection fraction (LVEF) 24 ± 8%, 71 <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo>, CRT-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> 67, conventional <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> matched controls 67, follow-up 31 ± 17 months] and monitored overall survival and the time to a first VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> episode </plain></SENT>
<SENT sid="5" pm="."><plain>Controls did not have <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>They were otherwise matched for age, LVEF, and follow-up duration </plain></SENT>
<SENT sid="7" pm="."><plain>Gender and underlying disease did not differ between the groups </plain></SENT>
<SENT sid="8" pm="."><plain>Kaplan-Meier analysis revealed more favourable <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>-free survival in CRT-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> vs. conventional <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> patients [hazard ratio (HR) 2.26, confidence interval (CI) 1.09-4.67, log rank P = 0.023] </plain></SENT>
<SENT sid="9" pm="."><plain>The difference persisted in the multivariate Cox regression analysis (HR 3.25, CI 1.18-8.93, P= 0.022) </plain></SENT>
<SENT sid="10" pm="."><plain>Overall survival was similar in both groups (HR 1.45, CI 0.55-3.82, P = 0.45) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> treated with CRT-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>, experience less and delayed VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> episodes compared with matched controls without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> receiving conventional <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>In the long-term, CRT appears to exert antiarrhythmic effects and to attenuate the particularly high <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>-related risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>The incremental benefit of adding the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> option to CRT pacing in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LBBB</z:e> patients appears questionable </plain></SENT>
</text></document>